Jaguar Health, Inc. (NASDAQ:JAGX)

BRIEF

published on 08/21/2025 at 15:05, 5 months 9 days ago

Jaguar Health vise une expansion mondiale pour Canalevia®

Jaguar Health Approbation De La FDA Canalevia Traitement De La Diarrhée Canine Sommet Sur La Santé Animale
PRESS RELEASE

published on 08/21/2025 at 15:00, 5 months 9 days ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health announces conditional FDA approval of Canalevia-CA1 for CID in dogs and strategic plans to expand indication for general diarrhea treatment globally. Participation in 2025 Animal Health Summit

FDA Approval Canalevia-CA1 Partnerships Animal Health Diarrhea Treatment
BRIEF

published on 08/19/2025 at 22:20, 5 months 11 days ago

Jaguar Health Announces Approval of All Proposals at Annual Meeting

Crofelemer FDA Approval Jaguar Health Annual Meeting Partnership Strategy
BRIEF

published on 08/19/2025 at 22:20, 5 months 11 days ago

Jaguar Health annonce l'approbation de toutes les propositions lors de son assemblée annuelle

Crofelemer Jaguar Health Approbation De La FDA Assemblée Annuelle Stratégie De Partenariat
PRESS RELEASE

published on 08/19/2025 at 22:15, 5 months 11 days ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte to provide updates on crofelemer trial results and regulatory pathway at Emerging Growth Conference. Annual meeting results and company strategy also discussed

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference Regulatory Pathway
BRIEF

published on 08/19/2025 at 15:05, 5 months 11 days ago

Jaguar Health's Napo Pharmaceuticals Seeks FDA Guidance on Crofelemer for Rare Pediatric Disease

Napo Pharmaceuticals Jaguar Health Crofelemer Trials FDA Meeting MVID Treatment
BRIEF

published on 08/19/2025 at 15:05, 5 months 11 days ago

Napo Pharmaceuticals, filiale de Jaguar Health, sollicite l'avis de la FDA sur le crofelemer pour le traitement d'une maladie pédiatrique rare.

Napo Pharmaceuticals Jaguar Health Réunion De La FDA Traitement MVID Essais Crofelemer
PRESS RELEASE

published on 08/19/2025 at 15:00, 5 months 11 days ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago

Napo Pharmaceuticals Crofelemer MVID FDA Meeting NASPGHAN 2025 Annual Meeting
BRIEF

published on 08/14/2025 at 14:05, 5 months 16 days ago

Croissance financière et projets futurs de Jaguar Health au deuxième trimestre 2025

Stratégie Financière Jaguar Health Croissance De Mytesi Chiffre D'affaires Du Deuxième Trimestre 2025 Recherche Sur Crofelemer
BRIEF

published on 08/14/2025 at 14:05, 5 months 16 days ago

Jaguar Health's Q2 2025 Financial Growth and Future Plans

Jaguar Health Financial Strategy Q2 2025 Revenue Mytesi Growth Crofelemer Research

Published on 01/31/2026 at 03:15, 1 hour 52 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 2 hours 47 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 3 hours 27 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 5 hours 7 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 6 hours 7 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 2 hours 21 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 7 hours 7 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 8 hours 56 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 8 hours 57 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 8 hours 59 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 18:40, 10 hours 27 minutes ago

ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 18:01, 11 hours 6 minutes ago

Emova Group - Résultats annuels 2024/25
Published on 01/30/2026 at 17:45, 11 hours 22 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 11 hours 22 minutes ago

Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 20 hours 37 minutes ago

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés

View all LES ECHOS COMFI WIRE

News